Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...
FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...
Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...
The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
A third CRL was issued for rivoceranib plus camrelizumab in first-line unresectable/metastatic HCC, driven by cGMP ...
Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...
The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...
In this interview with Targeted Oncology managing editor Sabrina Serani, Estelamari Rodriguez, MD, MPH, hematologist-oncologist at Sylvester Comprehensive Cancer Center, discusses ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results